|
|
|
|
|
Ergoloid Mesylate
drug data and news
Ergoloid Mesylate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ergoloid Mesylate | ||
| Brand Names/Synonyms | Alkergot; CCK 179; Circanol; Co-Dergocrine Mesylate; Deapril-St; Dihydroergotoxin Mesilat; Dihydroergotoxin Mesylate; Dihydroergotoxin Methanesulfonate; Dihydroergotoxine Mesilate; Dihydroergotoxine Mesylate; Dihydroergotoxine Methanesulfonate; Dihydroergotoxine Methanesulphonate; ERGOLOID MESYLATES; Ergoloid Mesylate; Ergoloid Mesylates; Ergoloid Mesylates [Usan]; Gerimal; Hydergin; Hydergine; Hydergine Lc; Hydrogenated Ergot Alkaloids; Ischelium; Redergin; Trigot | ||
| Indication | For use as an adjunct therapy for patients with dementia | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia. | ||
| Mechanism Of Action | Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels. | ||
| Ergoloid Mesylate News (When available) |
| ||
| Dosage Forms | CAPSULE; LIQUID; POWDER; POWDER FOR SOLUTION; SOLUTION; SYRUP; TABLET | ||
| Drug_Category | Adrenergic alpha-Antagonists; Nootropic Agents; Vasodilator Agents; Sympatholytics; ATC:C04AE01 | ||
| Absorption | Rapidly but incompletely (~ 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism. | ||
| Interactions |
Drug Interactions for Ergoloid Mesylate: No reported interactions. | ||
| Toxicity | Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C33H45N5O5 | ||
| Molecular Weight | 591.741 g/mol | ||
| Smiles String | CCC(C)(C)C1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. | ||
| Half Life | 3.5 hours | ||
| Protein Binding [%] | 98-99% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | Not Available | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00711 | ||
| CAS Registry Number | 8067-24-1 | ||
| KEGG Compound ID | C14055 | ||
| PubChem ID | SID:338422 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 176176 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |